Clinical trials: Neoadjuvant Treatment
Head and Neck Squamous Cell Carcinoma
Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
Objective: Primary objective: To evaluate the major pathologic response (mPR) of locally advanced head and neck cancer after paclitaxel and carboplatin-induction chemotherapy followed by surgery.
- Trial name
- NEOS (NCT05294900)
- Testing
- paclitaxel/carboplatin
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Yonsei University
Esophageal Cancer
CHFR Methylation Status Esophageal Cancer Study
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
- Trial name
- J10130 (NCT01372202)
- Testing
- Paclitaxel, Cisplatin, Oxaliplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-small Cell Lung Cancer
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in standard chemotherapy.
- Trial name
- NCT02157116
- Testing
- cisplatin, Docetaxel, Pegfilgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
Acute Myeloid Leukemia
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short.
- Trial name
- NCT04905407
- Testing
- Tamibarotene, Venetoclax, Azacitidine
- Where
- 28 sites in United States, France
- Volunteers
- 66 people
- Sponsor
- Syros Pharmaceuticals
Neoplasms, Breast
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
- Trial name
- CHERLOB (NCT00429299)
- Testing
- lapatinib, trastuzumab, paclitaxel
- Where
- 17 sites in Germany, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
HER2 Negative Breast Cancer
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced…
- Trial name
- NCT01527487
- Testing
- Eribulin, Cyclophosphamide, Docetaxel
- Where
- 15 sites in United States
- Volunteers
- 76 people
- Sponsor
- SCRI Development Innovations, LLC
Neoplasms, Breast
Treatment With Pazopanib for Neoadjuvant Breast Cancer
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a…
- Trial name
- NCT00849472
- Testing
- doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery
- Where
- 143 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis…
- Trial name
- OCTAVE (NCT01465763)
- Testing
- tofacitinib
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 614 people
- Sponsor
- Pfizer
Breast Neoplasm Female
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis.
- Trial name
- NCT03096418
- Testing
- Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison
Nonmalignant Neoplasm, Prostate Cancer
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
RATIONALE: Diagnostic procedures, such as MRI and magnetic resonance spectroscopy imaging, may help in learning how well dutasteride works in patients with benign prostatic hypertrophy and low-risk prostate cancer.
- Trial name
- NCT00706966
- Testing
- dutasteride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Crohn Disease
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03440372
- Testing
- Ozanimod
- Where
- 408 sites in United States, Argentina and 33 more
- Volunteers
- 625 people
- Sponsor
- Celgene
Diabetes Mellitus, Type 2
Treatment of GLP-1 for Diabetic Bariatric Patients
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process.
- Trial name
- NOVO-GLP1 (NCT04624672)
- Testing
- Semaglutide (1 Mg Dose)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Geisinger Clinic
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
The purpose of this study is to evaluate the clinical activity and safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-induction therapy in adult patients with WT1-positive AML presenting a suboptimal…
- Trial name
- NCT01051063
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
High Risk Prostate Cancer
Neoadjuvant BKM120 in High-risk Prostate Cancer
This is a phase II, study of BKM120 in patients with high-risk, localized prostate cancer. Eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy of the prostate to confirm high-risk disease and…
- Trial name
- NCT01695473
- Testing
- BKM120
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Won Kim
Multiple Myeloma
Velcade (Bortezomib) Consolidation After Transplant
The purpose of this study is to determine if bortezomib when added to consolidation treatment with thalidomide and prednisolone leads to an improved response in patients with multiple myeloma who have undergone autologous stem…
- Trial name
- VCAT (NCT01539083)
- Testing
- Thalidomide, Bortezomib, Cyclophosphamide
- Where
- 23 sites in Australia, China and 1 more
- Volunteers
- 256 people
- Sponsor
- Janssen Scientific Affairs, LLC
Triple-negative Breast Cancer
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window to chemotherapy with PDL1-inhibition…
- Trial name
- neoMono (NCT04770272)
- Testing
- Atezolizumab 840 MG in 14 ML Injection, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin
- Where
- Germany
- Volunteers
- 442 people
- Sponsor
- Palleos Healthcare GmbH
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Trial name
- NCT03698019
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 815 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)
HER-2 Positive Breast Cancer
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically…
- Trial name
- NCT01388647
- Testing
- eribulin, carboplatin, trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Vector Oncology
Crohn Disease
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03440385
- Testing
- Ozanimod
- Where
- 368 sites in United States, Australia and 29 more
- Volunteers
- 606 people
- Sponsor
- Celgene
Lymphoid Leukemia, Small Lymphocytic Lymphoma
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
The investigators propose a treatment strategy where patients are treated with induction chemoimmunotherapy consisting of rituximab + bendamustine for 6 cycles, followed by initiation of maintenance rituximab and lenalidomide…
- Conditions
- Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- NCT01754857
- Testing
- Bendamustine, Rituximab, Lenalidomide
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison